# US 2012/0252831 A1 · Compositions of opioid antagonists and methods for treating scleroderma therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252831 A1
- Document ID: US20120252831A1
- Status: Published application
- Kind: A1
- Application number: 13/076,590
- Filed: 2011-03-31
- Published: 2012-10-04
- Earliest claimed: 2011-03-31
- Assignees: Mustafa Nevzat Ilac Sanayii A.S.
- Inventors: Ibrahim Mustafa Iskender Pisak; Semra Bingol; Mehmet Levent Selamoglu; Mehmet Pisak
- Web page: https://patentgrep.com/patent/US20120252831A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61P 19/00: Drugs for skeletal disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are compositions comprising opioid antagonists, such as naltrexone naloxone, or nalmefene, or their pharmaceutically acceptable salts, and methods for treating scleroderma, including systemic sclerosis, therewith.

## Claims

### Claim 1

A method for treating scleroderma comprising administering to a subject in need thereof an effective amount of an opioid antagonist or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the opioid antagonist is naltrexone, naloxone, nalorphine, levallorphan, nalmefene, cyprodime, naltindole, or norbinaltorphimine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the opioid antagonist is naloxone.

### Claim 4 (depends on 1)

The method of claim 1, wherein the opioid antagonist is nalmefene.

### Claim 5 (depends on 1)

The method of claim 1, wherein the opioid antagonist is naltrexone.

### Claim 6 (depends on 5)

The method of claim 5, wherein the naltrexone has less than about 10% by weight of other steroisomers.

### Claim 7 (depends on 5)

The method of claim 5, wherein the naltrexone has less than about 5% by weight of other steroisomers.

### Claim 8 (depends on 1)

The method of claim 1, wherein the scleroderma is systemic sclerosis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the opioid antagonist is administered in the form of a composition comprising the opioid antagonist and at least one pharmaceutically acceptable excipient.

### Claim 10 (depends on 9)

The method of claim 9, wherein the composition is formulated for topical administration.

### Claim 11 (depends on 10)

The method of claim 10, wherein the opioid antagonist is present in an amount of about 0.1% to about 5% by weight of the composition.

### Claim 12 (depends on 10)

The method of claim 10, wherein the opioid antagonist is present in an amount of about 0.5% to about 2% by weight of the composition.

### Claim 13 (depends on 10)

The method of claim 10, wherein the opioid antagonist is present in an amount of about 1% by weight of the composition.

### Claim 14 (depends on 10)

The method of claim 10, wherein the composition is in the form of a gel, cream, ointment, liquid, suspension, solution, emulsion, foam, or aerosol.

### Claim 15 (depends on 10)

The method of claim 10, wherein the composition is administered to the subject by spreading or spraying the composition onto the affected area.

### Claim 16 (depends on 10)

The method of claim 10, wherein the opioid antagonist is administered in a total daily dose of up to about 150 mg/cm2 of skin.

### Claim 17 (depends on 10)

The method of claim 10, wherein the opioid antagonist is administered in a total daily dose of about 10 mg/cm2 to about 100 mg/cm2 of skin.

### Claim 18 (depends on 10)

The method of claim 10, wherein the opioid antagonist is administered in a total daily dose of about 50 mg/cm2 of skin.

### Claim 19 (depends on 9)

The method of claim 9, wherein the composition is formulated for oral administration.

### Claim 20 (depends on 19)

The method of claim 19, wherein the formulation is in the form of a tablet or capsule.

### Claim 21 (depends on 19)

The method of claim 19, wherein the opioid antagonist is present in an amount of about 0.1 mg to about 10 mg.

### Claim 22 (depends on 19)

The method of claim 19, wherein the opioid antagonist is present in an amount of about 1 mg to about 4.5 mg.

### Claim 23 (depends on 19)

The method of claim 19, wherein the opioid antagonist is present in an amount of about 2 mg.

### Claim 24 (depends on 1)

The method of claim 1, wherein the opioid antagonist is administered 1, 2, 3, 4, or 5 times daily.

### Claim 25 (depends on 1)

The method of claim 1, further comprising administering to the subject one or more additional agents effective to treat the scleroderma.

### Claim 26

A kit comprising a unit dose of an opioid antagonist and a label or printed instructions instructing the administration of the opioid antagonist to treat scleroderma.

### Claim 27 (depends on 26)

The kit of claim 26, wherein the scleroderma is systemic sclerosis.

### Claim 28 (depends on 26)

The kit of claim 26, wherein the administration is topical administration.
